Fig. 2: Distinct DNA fragments packaged in EVs released from pancreatic cancer and non-cancer cells. | Communications Biology

Fig. 2: Distinct DNA fragments packaged in EVs released from pancreatic cancer and non-cancer cells.

From: EV DNA from pancreatic cancer patient-derived cells harbors molecular, coding, non-coding signatures and mutational hotspots

Fig. 2

A Following DNA extraction from the EVs prepared by the kit-based method, a dsDNA-specific detection method was used to validate the presence of DNA molecules in the samples; representative of 3 experiments. Equal amount of dsDNA, 2 ng, was loaded on the Agilent 4200 TapeStation system using the genomic (B) or the D5000 (D) screen tape protocol; experiments were done at least three times. C The electropherograms showing distinct peaks for the control and cancer cells; 3 representatives from the 10 cell lines. E EV preparations were treated with DNAse I before DNA was extracted. A dsDNA-specific detection method was used to confirm the presence of DNA molecules as in (A). F–H The DNA fragments in samples from (E) were analyzed as described in (B, D). The activity of the DNAse I was confirmed by analyzing EV DNA from H6C7 (#1) or MiaPaCa2 (#2) digested with the DNAse I.

Back to article page